Biodexa Pharmaceuticals (BDRX) Income from Continuing Operations (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Income from Continuing Operations of 5297495.41 for Q2 2025, down 16.0% sequentially from 4566699.54 in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Income from Continuing Operations (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Income from Continuing Operations for 12 years, with the latest figure at 5297495.41 in Q2 2025.
- Quarterly Income from Continuing Operations changed N/A year-over-year to 5297495.41 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 23979473.14 (changed N/A YoY) and the FY2025 annual result came in at 8694257.16, down 8.75% from the prior year.
- Income from Continuing Operations fell to 5297495.41 in Q2 2025 per BDRX's latest filing, from 4566699.54 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 4566699.54 in Q4 2024 and troughed at 10415603.49 in Q4 2022.
- A 5-year average of 6575200.48 and a median of 5167883.84 in 2021 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2022: Income from Continuing Operations soared 78.13% in 2021, then fell 21.83% in 2022.
- Over 5 years, Income from Continuing Operations stood at 8549083.27 in 2021, then retreated by 21.83% to 10415603.49 in 2022, then climbed by 10.81% to 9290021.86 in 2023, then soared by 50.84% to 4566699.54 in 2024, then slipped by 16.0% to 5297495.41 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 5297495.41, 4566699.54, and 9290021.86 for Q2 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -5.30 Mn |
| Dec 31, 2024 | -4.57 Mn |
| Dec 31, 2023 | -9.29 Mn |
| Jun 30, 2023 | -4.83 Mn |
| Dec 31, 2022 | -10.42 Mn |
| Sep 14, 2022 | -4.62 Mn |
| Dec 31, 2021 | -8.55 Mn |
| Sep 17, 2021 | -5.04 Mn |
| Dec 31, 2020 | -31.78 Mn |
| Sep 10, 2020 | -23.04 Mn |
| Dec 31, 2019 | -15.11 Mn |
| Dec 31, 2018 | -18.57 Mn |
| Dec 31, 2016 | -15.37 Mn |
| Dec 31, 2015 | -44.50 Mn |
| Dec 31, 2014 | -15.59 Mn |
| Dec 31, 2013 | -7.91 Mn |